Form 4: Recursion Pharmaceuticals CFO Michael Secora Executes Stock Option Plan, Sells Shares

Chief Financial Officer of Recursion Pharmaceuticals, Michael Secora, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• Michael Secora, the CFO of Recursion Pharmaceuticals, executed transactions involving Class A Common Stock on March 12 and 13, 2024.
• These transactions involved the exercise of stock options at a price of $2.22 and the subsequent sale of shares at weighted average prices of $10.455 and $11.0326, respectively.
• The transactions were conducted under a pre-arranged 10b5-1 trading plan adopted on March 1, 2023.
• Secora's beneficial ownership of Class A Common Stock following these transactions is 1,204,179 shares.
• Secora also holds multiple stock options with varying exercise prices and expiration dates.

Sentiment

Score: 5

Explanation: Neutral sentiment. The transactions are part of a pre-arranged plan, but the sale of shares by the CFO could raise concerns among some investors.

Positives

• The transactions were pre-planned under a 10b5-1 trading plan, suggesting they were not based on insider information.
• The CFO is exercising options, which could be interpreted as a belief in the company's long-term prospects.

Negatives

• The CFO is selling shares, which could be perceived negatively by some investors.
• The sale of shares by a high-ranking officer may create short-term selling pressure on the stock.

Risks

• Further sales by the CFO could continue to exert downward pressure on the stock price.
• The market may interpret these transactions as a lack of confidence in the company's future performance, regardless of the 10b5-1 plan.

Industry Context

Insider transactions are common in publicly traded companies, and the use of 10b5-1 plans is a standard practice to avoid accusations of trading on non-public information. Investors often monitor these filings for signals about management's confidence in the company's prospects. Companies like Amgen, Gilead, and Vertex also have executives who regularly use 10b5-1 plans.

Comparison to Industry Standards

• Executive compensation packages in the biotech industry often include stock options as a significant component.
• The vesting schedules and exercise prices of these options are generally aligned with industry norms.
• The use of 10b5-1 trading plans is a common practice among executives at comparable companies to manage their stock holdings.
• For example, executives at companies like Moderna and BioNTech also utilize 10b5-1 plans for stock transactions.

Stakeholder Impact

• Shareholders may react to the news of the CFO selling shares.
• Employees may be affected by any potential impact on the company's stock price.
• The company's reputation could be affected depending on how the market interprets these transactions.

Key Dates